PAH Is the Focus of New Clinical Series Using CXA-10 Therapy

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

ph_pha focus

Complexa Inc., a biopharmaceutical company developing therapies to treat fibrosis and inflammation-related diseases, announced the successful completion of a Phase 1 clinical program for its lead drug candidate CXA-10, and the beginning of preparations for Phase 2 clinical trials for focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH) in 2016.

The announcement builds on a growing trend in PAH drug development that targets inflammation. Data on the cardiovascular and renal benefits obtained by administering CXA-10 to patients was recently presented at the 2015 American Society of Nephrology’s Kidney Week.


Read more:

A Conversation With Rare Disease Advocates